Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334703 | 0.76 | EGLN2 (0.49) | EGLN2KDM4EMAPK1MAPTALDH1A1 | |
| SCHEMBL14427965 | 0.67 | EGLN2 (0.46) | EGLN2KDM4EMAPK1MAPTALDH1A1 | |
| SCHEMBL14427966 | 0.65 | EGLN2 (0.44) | EGLN2KDM4EMAPK1MAPTALDH1A1 | |
| SCHEMBL5315895 | 0.65 | KDM4E (0.54) | EGLN2KDM4EMAPK1MAPTALDH1A1 | |
| SCHEMBL21120850 | 0.62 | IDO1 (0.39) | TSHRTDP1 | |
| SCHEMBL16151221 | 0.62 | EGLN2 (1.00) | EGLN2 | |
| SCHEMBL23055294 | 0.61 | ALDH1A1 (0.42) | EGLN2ALDH1A1 | |
| SCHEMBL18290888 | 0.59 | TSHR (0.55) | KDM4EALDH1A1TSHRSMN1; SMN2TDP1 | |
| SCHEMBL1537948 | 0.59 | ALDH1A1 (0.45) | EGLN2KDM4EALDH1A1GAASMN1; SMN2 | |
| SCHEMBL12609895 | 0.59 | DYRK1A (0.60) | EGLN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765825-A1 | CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES | AMGEN INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006004702-A1 | CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | EGLN2 4721/4885KDM4E 3908/4885MAPK1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.